120 related articles for article (PubMed ID: 37452634)
1. SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway.
Gu W; Qi G; Chen L
Iran J Immunol; 2023 Sep; 20(3):335-347. PubMed ID: 37452634
[TBL] [Abstract][Full Text] [Related]
2. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
3. OTX1 silencing suppresses ovarian cancer progression through inhibiting the JAK/STAT signaling.
Zhang Q; Li X; Ren L; Gu X; Xiao N; Li N
Tissue Cell; 2023 Jun; 82():102082. PubMed ID: 37027968
[TBL] [Abstract][Full Text] [Related]
4. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
5. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy.
Chen M; Wang S
Int Immunopharmacol; 2024 Mar; 130():111717. PubMed ID: 38387193
[TBL] [Abstract][Full Text] [Related]
6. Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation.
Zou Y; Padmanabhan S; Vancurova I
Methods Mol Biol; 2020; 2108():229-239. PubMed ID: 31939185
[TBL] [Abstract][Full Text] [Related]
7. m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R/JAK1/STAT3 signaling by sponging miR-647.
Wang R; Ye H; Yang B; Ao M; Yu X; Wu Y; Xi M; Hou M
Int Immunopharmacol; 2023 Nov; 124(Pt A):110879. PubMed ID: 37713785
[TBL] [Abstract][Full Text] [Related]
8. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
9. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
11. Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFNγ and Romidepsin in Ovarian Cancer Cells.
Padmanabhan S; Zou Y; Vancurova I
Methods Mol Biol; 2020; 2108():221-228. PubMed ID: 31939184
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J; Choudhuri J; Wang Q; Fang Y; Shi Y; Kamel J; Shah N; Sica RA; Kornblum N; Konopleva M; Mantzaris I; Shastri A; Gritsman K; Verma A; Goldfinger M; Goel S; Wang Y; Tian X
Leuk Lymphoma; 2023 Oct; 64(10):1662-1672. PubMed ID: 37424335
[TBL] [Abstract][Full Text] [Related]
14. MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
Li L; Zhang Y; Hu W; Zou F; Ning J; Rao T; Ruan Y; Yu W; Cheng F
J Cell Mol Med; 2023 Oct; 27(19):2922-2936. PubMed ID: 37480214
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
16. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
17. Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Iwasaki T; Kohashi K; Toda Y; Ishihara S; Yamada Y; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1451-1463. PubMed ID: 32951108
[TBL] [Abstract][Full Text] [Related]
18. SPI1-related protein inhibits cervical cancer cell progression and prevents macrophage cell migration.
Jin J; Du X; Zhou L; Yao D; Zou Q
J Obstet Gynaecol Res; 2022 Sep; 48(9):2419-2430. PubMed ID: 35770729
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K
Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]